

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-122024-0001296

Date: 24.1.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request for Information

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 September and 31 August (by year). For each therapy, break down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)

Drug	Total Patients (Initiated + Continuing)			
	Sep22- Aug23		Sep23- Aug24	
	Localised (M0)	Metastatic (M1)	Localised (M0)	Metastatic (M1)
Abiraterone + ADT	2	59	6	53
Abiraterone	0	0	0	0
Enzalutamide + ADT	7	104	10	100
Enzalutamide	0	0	0	0
Apalutamide + ADT	1	15	7	21
Apalutamide	0	0	0	0
Darolutamide + ADT	22	9	26	14
Darolutamide	0	0	0	0

2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)

Drug	Initiated Patients			
	Sep22- Aug23		Sep23- Aug24	
	Localised (M0)	Metastatic (M1)	Localised (M0)	Metastatic (M1)
Abiraterone + ADT	1	19	2	15
Abiraterone	0	0	0	0
Enzalutamide + ADT	1	27	3	18
Enzalutamide	0	0	0	0
Apalutamide + ADT	0	7	3	8

Apalutamide	0	0	0	0
Darolutamide + ADT	8	4	6	5
Darolutamide	0	0	0	0

3. Number of Patients for Whom Hormone Therapy Was Continued; for ICD-10 C61 / M0 and ICD-10 C61 / M1-M1c (localised & metastatic)

Drug	Continuing Patients			
	Sep22- Aug23		Sep23- Aug24	
	Localised (M0)	Metastatic (M1)	Localised (M0)	Metastatic (M1)
Abiraterone + ADT	1	40	4	38
Abiraterone	0	0	0	0
Enzalutamide + ADT	6	77	7	82
Enzalutamide	0	0	0	0
Apalutamide + ADT	1	8	4	13
Apalutamide	0	0	0	0
Darolutamide + ADT	14	5	20	9
Darolutamide	0	0	0	0

4. The hormone therapies of interest are:

1. Bicalutamide or Flutamide alone (ADT)
2. Abiraterone (Zytiga) in combination with any ADT
3. Abiraterone (Zytiga) – no ADT
4. Enzalutamide (Xtandi) in combination with any ADT
5. Enzalutamide (Xtandi) – no ADT
6. Apalutamide (Erleada) in combination with any ADT
7. Darolutamide (Nubeqa) in combination with any ADT
8. Darolutamide (Nubeqa) in combination with any ADT with docetaxel / cabazitaxel
9. A GnRH antagonist (degarelix, relugolix)
10. A GnRH agonist (gosereline, leuprorelin, triptorelin)

Please note, at Dudley Group NHS Foundation Trust, Abiraterone, enzalutamide, apalutamide and darolutamide are always given with ADT not as a monotherapy.

Bicalutamide, flutamide and the GnRH agonists and antagonists are not processed through the chemotherapy prescribing system and cross-referencing the dispensing system with patient notes would take an unreasonable amount of time.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

FOI/REF FOI-

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust